Ductal carcinoma *in situ* (DCIS), the most common type of preinvasive breast cancer, consists of clonal proliferation of cells that appear malignant and accumulate within the lumen of mammary ducts ([@bib3]). By definition, DCIS does not metastasise to the lymph nodes as the tumour is limited to the epithelial layer and does not reach lymphatic vessels.

Axillary surgery in patients with DCIS has changed dramatically over the years ([@bib27]). In the early 1980s, axillary dissection was the standard procedure, but metastases were rarely detected using conventional histology (\<1% [@bib28]). In the 1990s, the sentinel lymph node (SN) concept was introduced for the clinical management of breast cancer ([@bib13]; [@bib10]). Among patients with a preoperative diagnosis of DCIS, SN biopsy is used for patients with a higher likelihood of developing occult invasive lesions (high-risk DCIS: i.e., large, high-grade, or comedo-type tumours; or palpable or mammographic masses) and those undergoing mastectomy ([@bib17]; [@bib1]). To prevent false-negative diagnoses, pathologists began to concentrate on the evaluation of SNs by adopting a step-sectioning procedure ([@bib8]). Intensive examination of SNs resulted in an increase in the detection of metastases in patients with DCIS. A meta-analysis showed that the incidence of SN metastases is 3.7% in patients with a postoperative diagnosis of DCIS ([@bib1]).

The diagnostic accuracy of both DCIS and lymph node metastases is dependent on the rigour of the examination. If fewer sections from the primary tumour or lymph node are examined, more microinvasions or micrometastases may not be identified. In most of the previous reports on DCIS with nodal metastasis, histological examination procedures for primary tumours are not mentioned in detail or do not cover the entire tumour spread, particularly in large tumours. Thus, these previous reports do not rigorously exclude microinvasive cancers.

Similarly, conventional histopathological examinations of lymph nodes are non-standardised and have limited ability to detect metastases accurately due to the partial evaluation of nodes. The one-step nucleic acid amplification (OSNA) assay (Sysmex, Kobe, Japan) was developed to overcome these limitations of the histopathological examination of lymph nodes. This assay is approved and commercialised for clinical use throughout Europe and Japan. It can be used to assess whole lymph nodes, and yields semi-quantitative results for the detection of clinically relevant nodal metastases \>0.2 mm in size by the detection and amplification of cytokeratin 19 (CK19) mRNA ([@bib32]; [@bib34]; [@bib26]; [@bib31]; [@bib6]; [@bib29]). The OSNA assay can distinguish macrometastases (\>2 mm in size) and micrometastases (\>0.2 mm to ⩽2 mm in size) from low-volume metastases corresponding to isolated tumour cells (⩽0.2 mm in size) according to the Cancer Staging Manual of the Union International Contre le Cancer (UICC; [@bib30]). Previously, we showed that when the OSNA whole node assay is applied to invasive breast cancers, more metastases, particularly micrometastases, are detected than those detected by routine histopathological examinations ([@bib22]).

Therefore, we hypothesise that a combination of detailed histological examination of primary breast tumours and the OSNA whole lymph node assay can accurately elucidate the incidence and characteristics of node-positive DCIS and suggest the pathogenesis. In this single-centre retrospective cohort study, we compared the performance of the detection of SN metastases using the OSNA whole node assay and routine frozen-section (FS) histology using a 2-mm-sectioned lymph node in patients with DCIS examined in detail; this was done to reveal the non-sentinel node (nonSN) status as well as the clinicopathological characteristics of OSNA assay--positive patients.

Patients and methods
====================

Patients and tumours
--------------------

The study subjects consisted of consecutive patients with pure DCIS who underwent SN biopsy between January 2007 and March 2011 at the Cancer Institute Hospital, Tokyo, Japan. The exclusion criteria were as follows: (1) SN mapping without the use of a radioisotope tracer, (2) metastasis detected only in nonSNs, (3) previous excision of a primary tumour, (4) heterochronous ipsilateral breast cancer recurrence, (5) neoadjuvant drug therapy, and (6) male gender. Patients who underwent FS histology for detection of SN metastases after the introduction of the OSNA assay were also excluded. From 21 April 2009, onward, the OSNA assay, instead of the FS histology method, was used for the detection of SN metastases in our institute. Therefore, this study involves two distinct cohorts categorised on the basis of the method used for the detection of SN metastases: patients who were earlier assessed using FS histology examination (FS cohort) and patients who were later assessed by the OSNA assay (OSNA cohort). Furthermore, in September 2009, we switched the method of detection of further nonSN metastases from a permanent histological method to the OSNA assay.

When a patient had several mammographic findings, the priority for the determination of the findings was mass, calcification, architectural distortion, and focal asymmetric density. When a patient had several presurgical breast biopsies, the priority for the determination of the biopsy method was incisional biopsy, vacuum-assisted needle biopsy, needle biopsy without vacuum assistance, ductoscopic biopsy, and fine-needle aspiration cytology. The immunohistochemical cutoff for oestrogen and progesterone receptor positivity was 10% cell positivity irrespective of the intensity.

Histological examination of primary tumours
-------------------------------------------

Partial mastectomy materials were sectioned continuously from the nipple side to the periphery at 5-mm intervals. All sections were histologically examined with haematoxylin and eosin staining. Total mastectomy materials were sectioned continuously from the nipple to the periphery at 5- to 7-mm intervals. The sectioning was performed to cover the entire tumour spread using macroscopic and radiologic findings as references. Most of the sections within the tumour spread were histologically confirmed with haematoxylin and eosin staining.

Sentinel lymph node biopsy procedure
------------------------------------

The radioisotope tracer used was 1.5 mCi/ml 99mTc-phytate. One day prior to surgery, the tracer was injected into the intradermal and subdermal space in the tumour area and retro-tumoural space. In all cases, lymphoscintigraphy was performed 1 h after the injection. In addition, 2- to 3-ml indigo carmine (a vital dye; Daiichi Sankyo, Tokyo, Japan) was injected in the peri-tumoural space or areola at surgery. Before surgery for the primary tumour, SNs were identified using a hand-held gamma-probe with guidance from the staining of the vessels and nodes. Radioactive and/or blue nodes were considered SNs and excised. When one or more SNs were positive, complete axillary lymph node dissection was performed immediately.

Frozen-section histology for SNs
--------------------------------

All SNs were step sectioned at 2-mm intervals by surgeons. Two serial sections were taken for each 2-mm lymph node section. Each section was intraoperatively assessed by FS histology with haematoxylin and eosin staining. Immunohistochemistry was not routinely used for the evaluation of SNs. The FS specimens were reviewed and classified into three categories -- macrometastasis, micrometastasis, or negative -- according to the seventh edition of the UICC Staging Manual ([@bib30]).

Permanent histology for nonSNs
------------------------------

All nonSNs in axillary dissection materials were cut in half along the long axis after formalin fixation. One of the cut surfaces was examined after haematoxylin and eosin staining. Approximately 5--7 nodes were embedded in paraffin in a single cassette. Immunohistochemical staining was not used to evaluate nonSNs.

One-step nucleic acid amplification assay for SNs and nonSNs
------------------------------------------------------------

The OSNA assay for lymph nodes has been described previously in detail ([@bib32]). Briefly, after the removal of extranodal tissue, whole lymph nodes were homogenised with 4-ml lysis buffer solution (Lynorhag; Sysmex, Kobe, Japan) and centrifuged at 10 000 **g** at room temperature. A total of 2-*μ*l supernatant was analysed with the RD-100i System (Sysmex), an automated molecular detection system that uses a reverse transcription loop--mediated isothermal amplification method ([@bib21]), and the LynoampBC Kit (Sysmex). The degree of amplification was detected on the basis of a reaction by-product, pyrophosphate ([@bib19]). The resultant change in turbidity on precipitation of magnesium pyrophosphate in turn correlated with the CK19 mRNA copy number per microlitre of the original lysate via a standard curve established beforehand with three calibrators containing different CK19 mRNA copy numbers. A standard positive control sample containing 5000, copies/*μ*l CK19 mRNA and a negative control sample containing no CK19 mRNA were used for quality assurance in every assay run. Lymph nodes that exceeded the specified maximum weight of 600 mg were cut into two or more pieces and processed as separate nodes. Thus, up to four lymph nodes were analysed in a single run.

The numbers of CK19 mRNA copies per microlitre in the measurement sample as well as the 1 : 10 diluted sample were calculated; based on these copy numbers, the result (i.e., positive or negative) was assessed in accordance with the cutoff level determined in the study of [@bib32]). Positive nodes were categorised as ++, +, or +I (positive with inhibited reaction), according to the criteria shown in [Table 1](#tbl1){ref-type="table"}. Positive (++) and (+) were considered equivalent to UICC macrometastasis and micrometastasis, respectively ([@bib32]). Positive (+I) was considered to include both UICC macro- and micrometastasis.

All SNs and a small number of nonSNs surrounding SNs were assessed intraoperatively. Almost all nonSNs in axillary dissection materials were assessed postoperatively. The nonSNs were placed in tubes and immediately frozen at −80 °C in a deep freezer (My Bio Cube; Nihon Freezer, Tokyo, Japan). The frozen nonSNs were assessed at a later date, using the same protocol, as fresh nodes.

Statistical analyses
--------------------

To compare the patient characteristics of the FS and OSNA cohorts, Student\'s *t-*test (for age), the Mann--Whitney *U-*test (for the period from breast biopsy to surgery, number of SNs removed, and number of specimens examined), and the *χ*^2^-test with Yates\' continuity correction (for other characteristics) were performed. To compare the detection rates of SN metastases between the FS and OSNA cohorts, a two-population *Z*-test with Yates\' continuity correction was performed for SN metastases (positive *vs* negative). To reveal the characteristics of patients with OSNA assay--positive DCIS, Student\'s *t-*test, the Mann--Whitney *U-*test, and the *χ*^2^-test with Yates\' continuity correction were performed for the above-mentioned characteristics in the OSNA cohort. *P*-values \<0.05 were considered statistically significant, and confidence intervals were set at the 95% level. All statistical analyses were performed with the statistical software R (version 2.10.1, <http://www.r-project.org/>).

Results
=======

Patient characteristics
-----------------------

Between January 2007 and March 2011, 828 patients were diagnosed with pure DCIS of the breast, and 695 (83.9%) of them underwent SN biopsy. Of these 695 patients, 623 were eligible for this study. The FS and OSNA cohorts contained 338 and 285 patients, respectively. The demographic characteristics of both cohorts are presented in [Table 2](#tbl2){ref-type="table"}. All patients were Asian women. Almost all the characteristics of the two cohorts, except presurgical biopsy method (needle biopsy *vs* others), were similar; the proportion of patients in the OSNA cohort who received needle biopsy was higher than that in the FS cohort (OSNA 209 out of 285, 73.3% *vs* FS 219 out of 338, 64.8% *P*=0.022). The histological characteristics of the primary tumour were similar between both cohorts. The median number of specimens examined from surgically removed breast tissue was more than 20 blocks for both cohorts.

Detection of SN metastases
--------------------------

Sentinel lymph nodes were positive for metastasis more frequently in the OSNA cohort than in the FS cohort (OSNA 12 out of 285, 4.2% 95% confidence interval 2.3--7.4% *vs* FS 1 out of 339, 0.3% 95% confidence interval 0.0--1.9%, *P*=0.0018; [Table 3](#tbl3){ref-type="table"}).

Sentinel lymph node and nonSN status in SN-positive patients
------------------------------------------------------------

All SN-positive patients underwent axillary lymph node dissection. In the FS cohort, only one patient had SN metastasis. In this patient, two nodes involved macrometastases (case \#1, [Table 4](#tbl4){ref-type="table"}); however, there were no metastases in nonSNs. In the OSNA cohort, 12 patients had SN metastases (cases \#2--13). In all 12 patients, SN metastasis was confined to one node, and the CK19 mRNA copy number was low (median, 430 copies/*μ*l; mean, 652 copies/*μ*l; range, 250--1400 copies/*μ*l). Of these 12 patients, 4 underwent permanent histology examination (cases \#2--5) and 8 underwent the OSNA assay (cases \#6--13) for the detection of nonSN metastases. Of the latter eight patients, three had nonSN metastases (cases \#8, \#11, and \#12) and two had low CK19 mRNA expression in nonSNs (cases \#6 and \#10).

Characteristics of patients with OSNA assay--positive DCIS
----------------------------------------------------------

In the OSNA cohort, 12 patients had SN metastases and 273 did not have metastases. The number of SNs removed in the SN-positive patients was larger than that in the SN-negative patients (median, 3; range, 1--6 *vs* median, 2; range, 1--7, respectively, *P*=0.045; [Table 5](#tbl5){ref-type="table"}). Other characteristics including pathological size, grade, subtype, palpability, mammographic finding, breast biopsy method, and the period from biopsy to surgery were not significantly different between cohorts.

Discussion
==========

This study features a combination of detailed histological examination of primary breast tumours to exclude microinvasive cancers and whole lymph node analysis using the OSNA assay to detect micrometastases \>0.2 mm in size. To our knowledge, this is the first report in which all whole SNs in DCIS were evaluated using a molecular assay. The incidence of SN-positive DCIS in the FS cohort was very low compared with the results of previous studies ([@bib1]), even considering that FS histology is a less-precise examination than permanent histology ([@bib14]). Thus, the histological examination procedure for primary tumours adapted in this study appears to exclude patients with microinvasive cancers more thoroughly than procedures used in previous studies. In the patients with DCIS examined in detail, the OSNA whole node assay detected more cases of SN metastases than routine FS histology. Moreover, 4% of DCIS patients were found to have SN metastases.

One of the possible pathogeneses of nodal metastasis in DCIS is true metastases from occult invasive lesions of primary tumours. Occult invasive lesions can manifest in two forms: (1) occult invasion between the specimen surfaces of the surgical materials and (2) multicentric occult cancer in the conserved breast (i.e., in partial mastectomy cases) or in materials not examined (i.e., in total mastectomy cases). In terms of occult invasion between the specimen surfaces, although the present histological examination procedure for primary tumours is extensive, invasive lesions of \<5 mm in size can be missed by chance. Ductal carcinoma *in situ* patients who have large, high-grade or comedo-type tumours, or palpable or mammographic masses are more likely to have occult invasion ([@bib1]). However, none of these characteristics of high-risk DCIS were significantly correlated with OSNA-positive tumours. Furthermore, the possibility of multicentric cancers appears to be low, because almost all patients in this study had preoperative mammography, ultrasonography, and magnetic resonance imaging.

Another possible pathogenesis is false-positive results from the OSNA assay. Lymph nodes with contaminating epithelial cells, benign intranodal inclusions, or iatrogenic dissemination of benign epithelial or tumour cells can cause false-positive diagnoses. However, as we will discuss later, the incidences of such events appear to be low. Several clinical trials demonstrate a high specificity (96--98%) for the OSNA assay ([@bib34]; [@bib26]; [@bib31]; [@bib6]; [@bib29]).

The incidence of false-positive diagnoses appears to be low for several reasons. First, the rigorous SN biopsy with radioisotope tracer before breast surgery and the removal of extranodal tissue before homogenisation minimises contamination. Second, although benign intranodal epithelial inclusions such as heterotopic mammary glands, benign glandular inclusions, and benign Mullerian inclusions are inevitable ([@bib16]; [@bib24]; [@bib4]; [@bib7]), their presence is very rare in axillary lymph nodes. In a large series with more than 3500 specimens, only 7 occurrences (\<0.2%) of ectopic breast tissue in SNs were identified ([@bib16]). Moreover, the malignant transformation of benign epithelial inclusions is hypothesised in the genesis of nodal metastases in association with DCIS. However, only few cases of pelvic or para-aortic lymph nodes have been reported to date ([@bib25]). Third, a prior invasive diagnostic biopsy can iatrogenically displace benign epithelial or tumour cells into the lymphatic system; these dislocated cells can be passively transported to the SN ([@bib12]; [@bib18]; [@bib2]; [@bib33]). The results of a large cohort study show that surgical excision biopsy increases isolated tumour cells and micrometastases in SNs ([@bib33]). In this study, the number of patients who had preoperative needle biopsy of the primary breast lesion in the OSNA cohort was higher than that in the FS cohort. This supports the hypothesis that a mechanical displacement of epithelial cells rather than true metastatic deposition explains the higher detection rate of positive SNs with the OSNA assay. However, we did not find any significant differences in breast biopsy methods or the period from biopsy to surgery between the OSNA-positive and OSNA-negative patients. Moreover, an iatrogenic dissemination usually does not spread to nonSNs ([@bib33]). The OSNA assay can evaluate nonSN status more accurately than routine single-section permanent histology ([@bib22]). In this study, five of eight patients whose nonSNs were assessed by the OSNA assay had metastasis or low CK19 mRNA expression in their nonSNs. Thus, true metastases could have occurred in at least 60% of the patients with SN-positive DCIS.

Therefore, true metastases from occult invasion between the specimen surfaces or iatrogenic dissemination of benign epithelial or tumour cells can be considered the pathogenesis of nodal metastases in DCIS. However, the clinicopathological characteristics and nonSN status of SN-positive DCIS do not clearly support either pathogenesis. These results might be related to the low number of OSNA assay--positive patients. Further deeper-cut examination of the primary tumours and follow-up of the node-positive DCIS patients are needed to elucidate their pathogeneses. Deeper-cut examinations will reveal whether node-positive DCIS has occult invasion. In addition, the follow-up of node-positive DCIS patients will elucidate the prognostic impact of nodal metastases, as iatrogenic dissemination does not have any prognostic impact.

A potential limitation of the use of the OSNA whole node assay is the inability to store materials for other analyses. This could be a critical limitation when planning therapeutic strategies for DCIS patients with nodal metastasis. In fact, in a scenario of tumour heterogeneity, it is not always the case that the *in situ* component should have the same hormone receptor status and HER2 profile of the nodal metastases. Another potential limitation in the use of the OSNA whole node assay for the analysis of nodes is its inability to find other possible coexisting pathologies such as lymphomas.

The management of SN-positive DCIS through further axillary lymph node dissection and adjuvant systemic therapy remains controversial ([@bib1]). Regarding axillary dissection, it is difficult to manage patients who have metastases with DCIS differently from those with invasive cancer, because surgeons cannot know the final pathology of the primary tumour intraoperatively. For invasive cancers, current guidelines recommend further axillary dissection for patients with SN metastases ([@bib15]; [@bib20]). Therefore, in this study, all patients with node-positive DCIS underwent further axillary dissection. According to the results of the American College of Surgeons Oncology Group Z-0011 trial, further axillary dissection is unnecessary for patients with only one or two positive SNs who have undergone partial mastectomy with radiation therapy and systemic chemotherapy ([@bib11]). However, systemic chemotherapy is sometimes merely overtreatment. Furthermore, there is no evidence supporting the omission of safe axillary dissection in patients who have undergone total mastectomy.

Adjuvant systemic therapy for patients with node-positive DCIS is also controversial. Considering possible occult microinvasion in primary tumours and the low tumour burden in SNs, node-positive DCIS might be treated as pT1miN1miM0 according to the seventh UICC staging. For patients with pT1miN1miM0 tumours, the current guidelines recommend considering endocrine therapy for hormone receptor--positive tumours and chemotherapy for hormone receptor--negative tumours ([@bib20]). However, adjuvant systemic therapy, particularly chemotherapy, can be overtreatment for node-positive DCIS as the 10-year survival rate of pure DCIS approaches 98% ([@bib5]), and the possibility of iatrogenic epithelial dissemination cannot be ruled out.

In conclusion, whole lymph node analysis using the OSNA assay detected more SN metastases than FS histology with 2-mm-sectioned nodes in DCIS patients examined in detail. The true metastases from occult invasion of the primary tumour or iatrogenic dissemination of benign epithelial or tumour cells by the preoperative breast biopsy can be cited as the pathogenesis of nodal metastases in DCIS. However, the clinicopathological characteristics and nonSN status of SN-positive DCIS do not clearly support either pathogenesis. Further deeper-cut examination of the primary tumours and follow-up of node-positive DCIS patients are needed to clearly elucidate the pathogenesis.
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###### Definition of positive lymph nodes using the one-step nucleic acid amplification assay and correspondence of the results to macrometastases (\>2 mm in size) and micrometastases (\>0.2 mm to ⩽2 mm in size)

                                                  **CK19 mRNA (copy/*****μ*****l) in diluted sample**   
  ----------------------------------------------- ----------------------------------------------------- ----------
  *CK19 mRNA (copy/*μ*l) in measurement sample*                                                         
   ⩾5000                                          Positive (++) Equivalent to macrometastasis            
   250--5000                                      Positive (+) Equivalent to micrometastasis             
   \<250                                          Positive (+I)[a](#t1-fn2){ref-type="fn"}              Negative

Abbreviations: CK19=cytokeratin 19; (+I)=positive with inhibited reaction.

Positive (+I) includes both macro- and micrometastases.

###### Patient and tumour characteristics between the frozen-section histology and OSNA cohorts

                                                  **Frozen section**   **OSNA**                   
  ----------------------------------------------- -------------------- ------------- ----- ------ ------------
  No. of patients                                 338                  100           285   100     
                                                                                                   
  *Age (years)*                                                                                   0.89
   Median (range)                                 50 (20--80)          50 (26--83)                
                                                                                                   
  *Palpability*                                                                                   0.81
   Palpable                                       131                  38.8          114   40.0    
   Non-palpable                                   207                  61.2          171   60.0    
                                                                                                   
  *Mammographic findings*                                                                         0.55
   Mass                                           40                   11.8          38    13.3    
   Calcification                                  200                  59.2          176   61.8    
   Others                                         31                   9.2           27    9.5     
   None                                           67                   19.8          44    15.4    
                                                                                                   
  *Breast biopsy method*                                                                          0.022\*^a^
   Incisional                                     1                    0.3           1     0.4     
   Needle with vacuum assistance                  168                  49.7          176   61.8    
   Needle without vacuum assistance               51                   15.1          33    11.6    
   Ductoscopic                                    19                   5.6           9     3.2     
   Cytology only                                  99                   29.3          66    23.2    
                                                                                                   
  *Period from breast biopsy to surgery (days)*                                                   0.64
   Median (range)                                 62 (6--765)          67 (7--887)                
                                                                                                   
  *SN identification*                                                                             0.36
   Radioisotope alone                             105                  31.1          78    27.4    
   Radioisotope plus dye                          233                  68.9          207   72.6    
                                                                                                   
  *No. of SN removed*                                                                             0.060
   Median (range)                                 2 (1--6)             2 (1--7)                   
                                                                                                   
  *Breast surgery*                                                                                0.63
   Partial mastectomy                             194                  57.4          170   59.6    
   Total mastectomy                               144                  42.6          115   40.4    
                                                                                                   
  *No. of specimen examined (blocks)*                                                             0.060
   Median (range)                                 21 (5--93)           22 (6--85)                 
                                                                                                   
  *Pathological size (cm)*                                                                        0.81
   ⩽2.0                                           76                   22.5          68    23.9    
   2.1--4.0                                       113                  33.4          94    33.0    
   4.1--6.0                                       83                   24.6          60    21.1    
   \>6.0                                          66                   19.5          63    22.1    
                                                                                                   
  *Subtype*                                                                                       0.26
   Comedo                                         131                  38.8          97    34.0    
   Non-comedo                                     207                  61.2          188   66.0    
                                                                                                   
  *Nuclear grade*                                                                                 0.22
   1                                              192                  56.8          160   56.1    
   2                                              88                   26.0          88    30.9    
   3                                              58                   17.2          37    13.0    
                                                                                                   
  *Oestrogen receptor*                                                                            0.36
   +                                              274                  81.1          240   84.2    
   −                                              64                   18.9          45    15.8    
                                                                                                   
  *Progesterone receptor*                                                                         0.88
   +                                              227                  67.2          194   68.1    
   −                                              111                  32.8          91    31.9    

Abbreviations: OSNA=one-step nucleic acid amplification; SN=sentinel lymph node. ^a^*P*-value for needle *vs* others. \**P*\<0.05.

###### Detection of sentinel lymph node metastases between the frozen-section histology and OSNA cohorts

             **Frozen section**           **OSNA**                                     
  ---------- -------------------- ------ ---------- ---------- ----- ------ ---------- --------
  Positive   1                    0.3     0.0--1.9   Positive  12    4.2     2.3--7.4  0.0018
  Negative   337                  99.7               Negative  273   95.8               

Abbreviations: CI=confidence intervals; OSNA=one-step nucleic acid amplification.

###### Sentinel and non-sentinel node status in patients with ductal carcinoma *in situ* with sentinel node metastasis

              **Sentinel node status**        **Non-sentinel node status**                                                  
  ---- -------------------------------------- ------------------------------ ------- --------- -------------- ------ ------ --------
  1     Histology[a](#t4-fn2){ref-type="fn"}  2/2                             Macro     NA      Histology^b^  0/14    (−)      NA
  2                     OSNA                  1/1                              (+)     1400     Histology^b^  0/20    (−)      NA
  3                     OSNA                  1/3                              (+)      620     Histology^b^  0/15    (−)      NA
  4                     OSNA                  1/1                              (+)      260     Histology^b^  0/12    (−)      NA
  5                     OSNA                  1/2                              (+)      280     Histology^b^  0/11    (−)      NA
  6                     OSNA                  1/4                              (+)      780         OSNA      0/13    (−)     150
  7                     OSNA                  1/3                              (+)      460         OSNA      0/9     (−)      2
  8                     OSNA                  1/2                             (+I)    250^c^        OSNA      1/6     (+I)   330^c^
  9                     OSNA                  1/4                              (+)      270         OSNA      0/14    (−)      0
  10                    OSNA                  1/5                              (+)      400         OSNA      0/26    (−)     240
  11                    OSNA                  1/1                              (+)     1400         OSNA      1/15    (+)     780
  12                    OSNA                  1/3                             (+I)    1300^c^       OSNA      2/22    (++)    7800
  13                    OSNA                  1/6                              (+)      400         OSNA      0/14    (−)      0

Abbreviations: CK19=cytokeratin 19; NA=not available; OSNA=one-step nucleic acid amplification assay; (+I)=positive with inhibited reaction.

Frozen-section histology using a 2-mm-sectioned lymph node. ^b^Permanent histology using a single-sectioned lymph node. ^c^CK19 mRNA copy numbers in the diluted samples.

###### Patient and tumour characteristics between SN-negative and SN-positive groups in the OSNA cohort

                                                  **SN negative**   **SN positive**               
  ----------------------------------------------- ----------------- ----------------- ---- ------ ---------
  No. of patients                                 273               100               12   100     
                                                                                                   
  *Age (years)*                                                                                   0.71
   Median (range)                                 50 (26--83)       54 (37--75)                   
                                                                                                   
  *Palpability*                                                                                   0.86
   Palpable                                       110               40.3              4    33.3    
   Non-palpable                                   163               59.7              8    66.7    
                                                                                                   
  *Mammographic findings*                                                                         0.75
   Mass                                           36                13.2              2    16.7    
   Calcification                                  169               61.9              7    58.3    
   Others                                         25                9.2               2    16.7    
   None                                           43                15.8              1    8.3     
                                                                                                   
  *Breast biopsy method*                                                                          0.42^a^
   Incisional                                     1                 0.4               0    0.0     
   Needle with vacuum assistance                  169               61.9              7    58.3    
   Needle without vacuum assistance               30                11.0              3    25.0    
   Ductoscopic                                    7                 2.6               2    16.7    
   Cytology only                                  66                24.2              0    0.0     
                                                                                                   
  *Period from breast biopsy to surgery (days)*                                                   0.22
   Median (range)                                 65 (7--887)       82 (13--281)                  
                                                                                                   
  *SN identification*                                                                             0.60
   Radioisotope alone                             76                27.8              2    16.7    
   Radioisotope plus dye                          197               72.2              10   83.3    
                                                                                                   
  *No. of SN removed*                                                                             0.045\*
   Median (range)                                 2 (1--7)          3 (1--6)                      
                                                                                                   
  *Breast surgery*                                                                                0.84
   Partial mastectomy                             163               59.7              7    58.3    
   Total mastectomy                               110               40.3              5    41.7    
                                                                                                   
  *No. of specimen examined (blocks)*                                                             0.12
   Median (range)                                 22 (6--85)        30 (12--54)                   
                                                                                                   
  *Pathological size (cm)*                                                                        0.41
   ⩽2.0                                           67                24.5              1    8.3     
   2.1--4.0                                       90                33.0              4    33.3    
   4.1--6.0                                       56                20.5              4    33.3    
   \>6.0                                          60                22.0              3    25.0    
                                                                                                   
  *Subtype*                                                                                       0.72
   Comedo                                         94                34.4              3    25.0    
   Non-comedo                                     179               65.6              9    75.0    
                                                                                                   
  *Nuclear grade*                                                                                 0.89
   1                                              154               56.4              6    50.0    
   2                                              84                30.8              4    33.3    
   3                                              35                12.8              2    16.7    
                                                                                                   
  *Oestrogen receptor*                                                                            0.75
   +                                              229               83.9              11   91.7    
   −                                              44                16.1              1    8.3     
                                                                                                   
  *Progesterone receptor*                                                                         0.83
   +                                              185               67.8              9    75.0    
   −                                              88                32.2              3    25.0    

Abbreviations: OSNA=one-step nucleic acid amplification; SN=sentinel lymph node. ^a^*P*-value for needle *vs* others. \**P*\<0.05.
